No Data
Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
Ainos AIMD AI Ainos Flora Leverage; Bio-Path BPTH Phase 2 Data
Express News | Ainos Inc - Clinical Trials for AI Nose-Powered Ainos Flora Device Moves Forward With 75Meaningful Case Results
Express News | Ainos Inc - Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by Nvidia Cuda
Ainos Inc applies for up to $200 million hybrid shelf — SEC filing
Ainos Inc applies for up to $200 million hybrid shelf — SEC filing
Express News | Ainos Inc Files for Mixed Shelf of up to $200 Mln – SEC Filing
No Data